In recent years, there has been an increase in reports of spurious semaglutides, belonging to the brand Ozempic, being distributed through regular supply chains in Brazil, the United Kingdom, and the United States. These falsified products were discovered by the World Health Organization (WHO) through its Global Surveillance and Monitoring System (GSMS) in 2022. Dr. Yukiko Nakatani, WHO Assistant Director-General for Essential Medicines and Health Products, urged all stakeholders to discontinue the use of suspicious medicines and report any concerns to relevant authorities.
Ozempic’s authentic manufacturer confirmed that the falsified semaglutides were identified through batch and serial numbers. These semaglutides are intended to help individuals manage their blood sugar and appetite levels, as well as reduce the risk of cardiovascular disease. However, due to their high cost, semaglutides are not recommended by WHO for diabetes treatment. Dr. Nakatani emphasized the importance of healthcare professionals, regulatory authorities, and the public being vigilant about these falsified medications. It is crucial to report any adverse effects, lack of effectiveness, or suspected falsification to the appropriate authorities.
Individuals who may have unknowingly received fake products are advised not to use them and seek medical assistance if they experience any side effects. To prevent falling victim to counterfeit medications, WHO advised purchasing prescribed products only from licensed physicians rather than online or from unfamiliar sources. Individuals should follow prescribed usage instructions, verify lot and serial numbers, inspect product integrity, and examine label quality to ensure they are using authentic medications.
The WHO also noted that consuming counterfeit or fake products can pose serious health risks and potential life-threatening consequences. Semaglutides are just one example of how fraudulent practices can compromise patient safety. It is essential that all stakeholders take measures to prevent such incidents from happening again in the future.
In conclusion, it is important for healthcare professionals and patients alike to be aware of the dangers posed by counterfeit medications like Ozempic’s spurious semaglutides. By taking steps such as verifying product authenticity before use and reporting any concerns to relevant authorities when necessary
